New combo therapy shows promise for hard-to-treat colorectal cancer
NCT ID NCT05504252
First seen Jan 07, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tests whether adding an immunotherapy drug (nivolumab) to standard chemotherapy can help control or shrink metastatic colorectal cancer that has not responded to other treatments. About 80 adults with a specific type of colorectal cancer (pMMR/MSS) will receive this combination. The goal is to see if the treatment can stop the cancer from growing and possibly allow for surgery to remove remaining tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Akershus University Hospital
Lørenskog, Akershus, 1478, Norway
-
Oslo University Hospital
Oslo, Akershus, 0424, Norway
-
St Olavs Hospital
Trondheim, Trøndelag, 7006, Norway
Conditions
Explore the condition pages connected to this study.